受强制性开放获取政策约束的文章 - Ganesh Mugundu了解详情
无法在其他位置公开访问的文章：1 篇
Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC‐MS/MS cocktail assays and RT‐PCR
L Liu, GM Mugundu, BJ Kirby, D Samineni, PB Desai, JD Unadkat
Biopharmaceutics & drug disposition 33 (4), 207-217, 2012
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：9 篇
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and …
A Gupta, GM Mugundu, PB Desai, KE Thummel, JD Unadkat
Drug metabolism and disposition 36 (6), 1172-1180, 2008
强制性开放获取政策： US National Institutes of Health
A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma
E Méndez, CP Rodriguez, MC Kao, S Raju, A Diab, RA Harbison, ...
Clinical Cancer Research 24 (12), 2740-2748, 2018
强制性开放获取政策： US National Institutes of Health
The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects
J Tong, N Dave, GM Mugundu, HW Davis, BD Gaylinn, MO Thorner, ...
European journal of endocrinology 168 (6), 821-828, 2013
强制性开放获取政策： US National Institutes of Health
Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
N Takebe, AR Naqash, G O'Sullivan Coyne, S Kummar, K Do, A Bruns, ...
Clinical Cancer Research 27 (14), 3834-3844, 2021
强制性开放获取政策： US National Institutes of Health
Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes
GM Mugundu, L Sallans, Y Guo, EA Shaughnessy, PB Desai
Drug Metabolism and Disposition 40 (2), 389-396, 2012
强制性开放获取政策： US National Institutes of Health
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
M Någård, ML Ah-See, K So, M Vermunt, F Thistlethwaite, M Labots, ...
Cancer Chemotherapy and Pharmacology 86, 97-108, 2020
强制性开放获取政策： Cancer Research UK, National Institute for Health Research, UK
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19 and CYP3A4 in patients with advanced solid tumors
M Någård, ML Ah-See, K So, J Strauss, T Wise-Draper, H Safran, D Wang, ...
Cancer Research 80 (16_Supplement), 3035-3035, 2020
强制性开放获取政策： US National Institutes of Health
Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study
M Någård, ML Ah-See, K So, J Strauss, T Wise-Draper, H Safran, D Wang, ...
Cancer Research 80 (16_Supplement), 591-591, 2020
强制性开放获取政策： US National Institutes of Health
Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations
G Moorthy, GP Pouliot, L Graham, E Pilling, L Jung, R Alcobi, Y Zhu, Y Li, ...
British Journal of Clinical Pharmacology 89 (9), 2775-2787, 2023
强制性开放获取政策： Forskningsrådet för arbetsliv, hälsa och välfärd
出版信息和资助信息由计算机程序自动确定